Ascidian Therapeutics

News

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.